This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Markets Book Profits as Vaccine Rally Stalls; DASH Jumps 86% on IPO
by Mark Vickery
DoorDash (DASH) shares closed its first day on the New York Stock Exchange at $189 per share.
IPO Market Set to Thrive in December
by Zacks Equity Research
IPO Market Set to Thrive in December
Amgen's (AMGN) KRAS Inhibitor Gets Breakthrough Tag for NSCLC
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy status on Amgen's (AMGN) KRAS inhibitor, sotorasib, for treating patients with advanced/metastatic non-small-cell lung cancer with KRAS G12C mutation.
DoorDash IPOs at $102, Vaccine Rally Cooling
by Mark Vickery
DoorDash is pricing its Initial Public Offering at $102 per share, for a valuation of $38.7 billion.
Stock Market News for Dec 9, 2020
by Zacks Equity Research
U.S. stocks closed higher on Tuesday as investors¿¿¿ sentiment got a boost from positive news on the COVID-19 vaccine front that overshadowed worries of surging coronavirus cases and a record number of hospitalizations, and slow progress in the sanction of another financial aid.
Curis (CRIS) Skyrockets on Promising Phase I Pipeline Updates
by Zacks Equity Research
Curis' (CRIS) hematologic malignancy candidate, CA-4948, shows promising activity in early-stage studies evaluating it in patients with either acute myeloid leukemia or non-Hodgkin's lymphoma. Stock up 350%.
5 Materials Stocks to Make the Most of Economic Recovery
by Zacks Equity Research
U.S. economy is poised for a rebound on positive COVID-19 vaccine developments and hopes of a fiscal stimulus, making it prudent to invest in stocks like Bunge (BG) and Cabot (CBT) from the materials sector.
Fate (FATE) Surges on Favorable Phase I Data on FT596 at ASH
by Zacks Equity Research
Fate (FATE) stock up on positive data from its early-stage study on its NK cell product candidate at ASH.
The Zacks Analyst Blog Highlights: Apple, Berkshire Hathaway, Johnson & Johnson, Lockheed Martin and PNC Financial Services Group
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Berkshire Hathaway, Johnson & Johnson, Lockheed Martin and PNC Financial Services Group
J&J (JNJ) Files BLA for Lung Cancer Candidate Amivantamab
by Zacks Equity Research
J&J (JNJ) files a BLA to the FDA for amivantamab for the treatment metastatic non-small cell lung cancer with EGFR Exon 20 insertion mutations.
Pharma Stock Roundup: Approval of PFE/BNTX Coronavirus Vaccine in UK, Other Updates
by Kinjel Shah
Pfizer (PFE) COVID-19 vaccine gets approval for emergency use in the United Kingdom while Roche's (RHHBY) Xolair gets FDA nod for new indication.
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed at $149 in the latest trading session, marking a +0.58% move from the prior day.
J&J (JNJ) Acquires Rights for Hemera Biosciences' Gene Therapy
by Zacks Equity Research
Johnson & Johnson's (JNJ) Janssen acquires rights to investigational gene therapy, HMR59, for the treatment of geographic atrophy.
AbbVie (ABBV) Signs New Cancer/Immunology Deal With Frontier
by Zacks Equity Research
AbbVie (ABBV) signs a global deal with Frontier Medicines to make innovative therapies and E3 degraders against difficult-to-drug targets.
Top Research Reports for Apple, Berkshire Hathaway & Johnson & Johnson
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Berkshire Hathaway Inc. (BRK.B) and Johnson & Johnson (JNJ).
Will Americans Get COVID-19 Vaccine Sooner Than Europeans?
by Kinjel Shah
Moderna (MRNA), and Pfizer (PFE)/BioNTech (BNTX) file for emergency use authorization of their COVID-19 vaccine candidates in Europe
Should iShares Morningstar LargeCap Value ETF (JKF) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JKF
Moderna (MRNA) Seeks Nod for Emergency Use of COVID-19 Vaccine
by Zacks Equity Research
Moderna's (MRNA) coronavirus vaccine achieves efficacy rate of 94.1% in primary efficacy analysis. The company files for Emergency Use Authorization to the FDA.
AstraZeneca (AZN) Forxiga Approved in Japan for Heart Failure
by Zacks Equity Research
AstraZeneca (AZN) Forxiga is approved in Japan for chronic heart failure (HF) in patients who are receiving standard of care.
Should iShares Russell Top 200 Value ETF (IWX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWX
Liquidia (LQDA) PAH Drug Gets FDA's Complete Response Letter
by Zacks Equity Research
The CRL issued to the NDA for Liquidia's (LQDA) LIQ861 stated that the FDA cannot approve the NDA in its present form
How Does AstraZeneca's COVID-19 Vaccine Data Compare to Others'?
by Kinjel Shah
Interim data from late-stage studies on AstraZeneca (AZN) COVID-19 vaccine shows that the candidate was, on an average, about 70% effective in preventing COVID-19.
3 Coronavirus Vaccine Makers Near Finish Line in November
by Zacks Equity Research
Positive developments related to coronavirus vaccine candidates have supported stock markets in November. Three leading coronavirus vaccine candidates achieve encouraging efficacy rate.
Pfizer/BioNTech Seek Nod for Emergency Use of COVID-19 Vaccine
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate is 95% effective in final analysis.
Is Johnson & Johnson (JNJ) a Suitable Pick for Value Investors?
by Zacks Equity Research
Is Johnson & Johnson (JNJ) a great pick from the value investor's perspective right now? Read on to know more.